Since investing is pure speculation anyhow, I think today's PR is the prelude to another announcement. "....we look forward to establishing the right partnership to further the clinical development pathway for leronlimab in the treatment of fibrosis of the liver and potentially other organs, such as the lungs and heart.”

I am also glad we stuck with the name Leronlimab!